THE Therapeutic Goods
Administration has approved an
alternative to GlaxoSmithKline
Australia’s Bactroban (mupirocin)
20mg/g ointment tubes, which
the firm has confirmed is in short
supply (PD 03 May).
GSK has advised the TGA
that the shortage is related to
manufacturing issues which are
expected to be resolved by Nov.
The TGA has approved a section
19A exemption for the importation
of an alternative product, which is
now available.
Therapeutic goods advertising
rules mean PD is unable to publish
further details about the alternative
product, but information including
where it can be obtained is now
online at tga.gov.au.
Any adverse events involving the
alternative should be reported, the
TGA advised.The above article was sent to subscribers in Pharmacy Daily's issue from 30 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 May 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.